{"entity":{"id":"nct04728893","kind":"trial","name":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","aka":[],"tldr":"A phase 2 trial of Nemtabrutinib in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) is a phase 2 interventional study registered as NCT04728893 by Merck Sharp & Dohme LLC, with 490 participants planned, started 2021-04-05 and due to reach its primary completion in 2029-01-04. Interventions recorded: Nemtabrutinib. Conditions listed: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04728893","url":"https://clinicaltrials.gov/study/NCT04728893"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["nemtabrutinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04728893","phase":"2","setting":"A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies","sponsor":"Merck Sharp & Dohme LLC","enrolled":490,"outcomes":[]},"route":"/trials/nct04728893/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}